Clinical validation of the Virtual Reality Functional Capacity Assessment Test – Short List (VRFCAT‐SLx) for assessment of iADL functioning in early symptomatic dementia: Baseline performance and associations with standard measures

Clinical trials in preclinical and early symptomatic Alzheimer’s disease require increased precision for the assessment and monitoring of functional capacity. The Virtual Reality Functional Capacity Assessment Tool (VRFCAT) is a performance‐based assessment of function with the potential to serve this need. Prior work has demonstrated the VRFCAT’s validity and sensitivity as a measure of iADL functioning in subjective cognitive decline (Atkins et al., 2019), but pilot work in more cognitively impaired individuals indicated a risk of floor effects in some patients. The VRFCAT “Short List” (VRFCAT‐SLx) was developed to address this issue by modifying the test to reduce length and complexity. We present Baseline data from an ongoing clinical validation study of the VRFCAT‐SLx in participants with clinically characterized MCI/AD dementia